Results 141 to 150 of about 4,421 (195)

Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program. [PDF]

Diabetes Ther
Miller E, Davidson MB, Bajaj HS, Rosenstock J, Philis-Tsimikis A, Bergenstal RM, Case M, Ilag L, Threlkeld R, Levasseur E, Gelsey F.   +10 more
europepmc   +1 more source

Effects of Different Exogenous Insulin Analog Treatments on the Evaluation of Pancreatic Islet Function in Diabetes. [PDF]

J Diabetes Res
Ma YF, Neng QL, Ou Y, Zhou YK.
europepmc   +1 more source

Transition from CSII to second-generation basal insulin analogues in hospitalized T2DM patients: a CGM-based study. [PDF]

BMC Endocr Disord
Dong R, Liu H, Gu L, Zhao Q, Luo C, Zhang T, Kou X, Hu Y, Shi B, Guo H, Qiang W.   +10 more
europepmc   +1 more source

Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials

Diabetes and Metabolism, 2020
Insulin degludec is a new ultra-long-action basal insulin. Using treat-to-target protocols, controlled trials have shown comparable HbA reductions with insulin degludec and comparators in both type 1 and type 2 diabetes.
V Preumont, M Buysschaert
exaly   +2 more sources

Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes.

Diabetes, Obesity and Metabolism, 2022
AIMS: Limited data exist about the use of insulin degludec in the hospital. This multicentre, non-inferiority, open-label, prospective randomized trial compared the safety and efficacy of insulin degludec-U100 and glargine-U100 for the management of ...
David Lam, Katherine R Tuttle
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Degludec: A Novel Basal Insulin

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012
Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulin. Degludec, a novel basal insulin analog has the potential to overcome these
Sanjay, Kalra, Manash P, Baruah, Asfandyar K, Niazi   +2 more
openaire   +3 more sources

Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes

Expert Review of Clinical Pharmacology, 2017
INTRODUCTION: A fixed combination of basal insulin degludec and glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (IDegLira; 50 units degludec/1.8 mg liraglutide) has been developed as a once daily injection for the treatment of type 2 ...
Thomas Fremming Dejgaard, Sten Madsbad, Lauge Østergaard   +2 more
exaly   +2 more sources

Insulin degludec + liraglutide: a complementary combination

Expert Opinion on Biological Therapy, 2016
The treatment of patients with type 2 diabetes mellitus remains challenging, as it goes beyond adequate glycemic control, in particular addressing weight, blood pressure and other contributors to cardiovascular disease. In addition, the progressive nature of type 2 diabetes mellitus demands the intensification and combination of glucose lowering ...
K, Stinkens, B, Peene, C, Mathieu
openaire   +2 more sources

Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus

Drugs, 2013
Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-to-day variability in glucose ...
openaire   +3 more sources